New $575,000 Grant Targets mTOR Inhibitors for Cutaneous Sarcoidosis Trial
Sarcoidosis has never attracted research funding proportionate to the suffering it causes. The inflammatory condition, which forms abnormal clusters of immune cells in organs throughout the body, can be debilitating and sometimes fatal. Current pharmaceutical options are limited to general anti-inflammatory medications that address symptoms without touching the underlying disease process. That treatment gap is precisely what a new grant program from the Milken Institute and Ann Theodore Foundation aims to narrow.
The program, called ATF-SIM (Ann Theodore Foundation Sarcoidosis Inhibitor of mTOR), will award up to $575,000 over two years to support the design and execution of a Phase 2 investigator-initiated clinical trial. The target: mechanistic target of rapamycin (mTOR) inhibitors, a class of drugs that blocks a specific molecular pathway implicated in sarcoidosis pathology. Applications are open through April 20, 2026, with awardees to be selected in June 2026.
Why mTOR, and Why Now
The rationale for focusing on mTOR inhibitors is rooted in a small but encouraging 2024 clinical trial. In that study, 10 patients with cutaneous sarcoidosis - a form of the disease affecting the skin, which occurs in roughly one quarter of sarcoidosis cases - were treated with sirolimus, an mTOR inhibitor already approved by the U.S. Food and Drug Administration for other inflammatory indications. Seven of the 10 participants experienced sustained symptom improvement after completing treatment. That is a striking response rate for a disease with no disease-modifying treatment options, though the sample size is far too small to draw firm conclusions.
Skin involvement in sarcoidosis manifests as painful rashes, skin lesions, and subcutaneous growths. It is the second most commonly affected organ system after the lungs. For patients, it can mean visible disfigurement and chronic discomfort. For researchers, it offers a measurable, accessible outcome for clinical trials in a way that lung or cardiac sarcoidosis does not always permit.
The mTOR pathway sits at a biological intersection that makes it a logical target. It regulates immune cell proliferation and the formation of granulomas - the characteristic clusters of immune cells that define sarcoidosis. Blocking this pathway with drugs like sirolimus or its derivatives (a drug class called rapalogs) could, in theory, reduce granuloma formation and the damage it causes.
A Third Step in a Longer Program
ATF-SIM is the third sarcoidosis-focused initiative launched by the Milken Institute and Ann Theodore Foundation since 2020. The earlier programs - ATF-LOMAS (Learning Opportunities in Medicine and Sarcoidosis) and ATF-BSI (Breakthrough Sarcoidosis Initiative) - have collectively committed over $11 million to sarcoidosis research. The partnership has also published a Giving Smarter Guide identifying strategic investment opportunities in the field.
The new program is deliberately narrow in focus. Rather than supporting exploratory basic research, it targets a specific therapeutic class and a specific indication, with the explicit goal of generating data sufficient to support late-stage trials and eventual regulatory review. Melissa Stevens, executive vice president of strategic philanthropy at the Milken Institute, said the aim is to "advance this potential treatment toward late-stage clinical trials and regulatory approval for use in cutaneous sarcoidosis."
Honest Assessment of What Comes Next
The 2024 pilot study that motivates this grant had 10 participants. Phase 2 trials are larger and more rigorous, but they remain intermediate-stage evidence. A positive Phase 2 result would be meaningful but would not itself establish that mTOR inhibitors are safe and effective enough for broad clinical use in sarcoidosis - that requires Phase 3 confirmation. Patients and clinicians should understand that the current grant is funding the next step in a multi-step evidentiary process, not imminent access to a new treatment.
What the program does represent is a structured effort to move a credible hypothesis through the clinical testing pipeline in a disease where funding has historically been sparse. Lisa Spalding, spokesperson for the Ann Theodore Foundation, noted that ATF-SIM "augments but does not supplant" the parallel early-stage research efforts the foundation continues to support. The logic is sound: different stages of the development pathway require different types of investment, and attending only to early discovery while neglecting the translational middle stages is a common failure mode in neglected disease research.
For a condition affecting an estimated 150,000 to 200,000 Americans - disproportionately Black Americans, who develop sarcoidosis at rates roughly three times higher than white Americans - even a successful Phase 2 result would represent meaningful progress toward treatments that have been absent for too long.